EDB Investments agreed to invest $45m in Arcturus Therapeutics, a clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines. “The promising Phase 1/2 study results indicate that ARCT-021 could be effective as a single administration, which differentiates this investigational vaccine from many other Covid -19 vaccines in development. ARCT-021 has the potential to provide important public health benefits by greatly facilitating broad administration across multiple populations worldwide,” Professor Ooi Eng Eong, Arcturus’ Vaccine Platform member of Scientific Advisory Board.